

Current and Emerging Therapies for

FOLLICULAR LYMPHOMA:

Solving Practice Challenges in Community-Based Interprofessional Care Teams

Dear Colleague,

Thank you for your recent participation in the activity *[Current and Emerging Therapies for Follicular Lymphoma: Solving Practice Challenges in Community-Based Interprofessional Care Teams](#)* with Dr. Jeremy Abramson and developed by the Annenberg Center for Health Sciences. As you continue to advance the care you provide to these patients, we'd like to summarize the key concepts from this activity:

- Although patients with follicular lymphoma typically respond well to initial therapy, the majority with advanced disease are not able to be cured leading to multiple lines of therapy, increased disease burden, and diminished quality of life.
- Several novel therapies are available beyond immunochemotherapy for relapsed/refractory disease, eg, axicabtagene ciloleucel, tisagenlecleucel, mosunetuzumab, and tazemetostat, all with varying treatment characteristics and safety profiles.
- Treatment selection and sequencing should be tailored to the patient, with consideration given to goals of therapy, patient characteristics, disease behavior, response to previous treatment, timing of disease progression (POD24), and patient preferences.
- Patients with relapsed/refractory disease should be considered for a clinical trial as a multitude of clinical trials are investigating novel therapies, eg, lisocabtagene maraleucel, odronextamab, epcoritamab, and others.
- Novel therapies for follicular lymphoma may lead to a wide range of toxicities. These toxicities are generally manageable, but require dedicated education, interprofessional collaboration, and effective communication for optimal patient outcomes.

We hope you will be able to participate in other accredited activities we offer (www.Annenberg.net). Thank you.

Regards,

The Annenberg Center Team